Diagnostic Value of Hematology Parameters Investigated for Hemophagocytic Lymphohistiocytosis
By LabMedica International staff writers Posted on 04 Aug 2021 |
Image: Mindray Double Chamber BC-5130 Auto Hematology Analyzer (Photo courtesy of Mindray)
Hemophagocytic lymphohistiocytosis (HLH) is a severe rare syndrome characterized by pathologic immune activation and hyperinflammation with harmful effects on multiple organs. The clinical presentations of HLH may include fever, cytopenias, splenomegaly, and hyperferritinemia, none of which is specific for this rare though life-threatening condition.
HLH shares similarities with other inflammatory states, for example, sepsis, and the high inflammatory response present in both states of HLH and sepsis provides overlapping clinical features, including fever and worsening clinical status. The differential diagnosis of HLH and sepsis is critically important because the life-saving aggressive immunosuppressive treatment, required in the effective HLH therapy, is absent in sepsis guidelines.
Clinical Laboratorians at the Zhejiang University School of Medicine (Hangzhou, China) conducted a retrospective study, involving 71 HLH patients, 105 sepsis patients, and 88 normal controls from January 2018 to December 2019. Children were classified as HLH if they meet at least five of the eight criteria of the International Histiocyte Society (2004-HLH criteria).
Peripheral blood samples were collected from all the participants for the first time. After treatment, peripheral blood samples from HLH patients were also collected. Complete blood counts were analyzed by hematology analyzer BC-5310 (Mindray, Nanshan, China). Red blood cell distribution width (RDW) and platelet distribution width (PDW) levels were collected from patients’ complete blood count, and RDW to platelet count ratio (RPR) was calculated as the ratio of RDW and platelet counts.
The scientists reported that nearly all the patients demonstrated fever and splenomegaly were present in more than 90% of the patients (fever: 70/71, 98.59%; splenomegaly: 68/71, 95.77%). Other clinical and laboratory tests included anemia (44/71, 61.97%), neutropenia (38/71, 53.52%), thrombocytopenia (33/71, 46.48%), hypofibrinogenemia (44/71, 61.97%), hypertriglyceridemia (28/71, 39.44%), hyperferritinemia (49/71, 69.01%), impaired NK-cell activity (47/71, 66.20%), and hemophagocytosis (20/24, 83.33%).
RDW, PDW, and RPR levels of the HLH patients were significantly higher than those of sepsis and normal controls. In ROC curve analysis of the RDW, PDW, and RPR for diagnosis of HLH, the area under the curve (AUC) reached to 0.78, 0.784, and 0.927, respectively. When using the criteria of RDW >13.75, PDW >13.30, and RPR >0.08, the sensitivity was 76.06%, 67.61%, and 84.51%, while the specificity was 68.57%, 85.71%, and 87.62%, respectively. After treatment of HLH patients, PDW and RPR were significantly reduced.
The authors concluded that their study indicated that cost-effective and easily calculated hematological parameters RDW, PDW, and RPR are novel indicators for differential diagnosis of HLH and sepsis. PDW and RPR could be additional biomarkers for monitoring therapeutic effects of HLH. The study was published on July 17, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Zhejiang University School of Medicine
Mindray
HLH shares similarities with other inflammatory states, for example, sepsis, and the high inflammatory response present in both states of HLH and sepsis provides overlapping clinical features, including fever and worsening clinical status. The differential diagnosis of HLH and sepsis is critically important because the life-saving aggressive immunosuppressive treatment, required in the effective HLH therapy, is absent in sepsis guidelines.
Clinical Laboratorians at the Zhejiang University School of Medicine (Hangzhou, China) conducted a retrospective study, involving 71 HLH patients, 105 sepsis patients, and 88 normal controls from January 2018 to December 2019. Children were classified as HLH if they meet at least five of the eight criteria of the International Histiocyte Society (2004-HLH criteria).
Peripheral blood samples were collected from all the participants for the first time. After treatment, peripheral blood samples from HLH patients were also collected. Complete blood counts were analyzed by hematology analyzer BC-5310 (Mindray, Nanshan, China). Red blood cell distribution width (RDW) and platelet distribution width (PDW) levels were collected from patients’ complete blood count, and RDW to platelet count ratio (RPR) was calculated as the ratio of RDW and platelet counts.
The scientists reported that nearly all the patients demonstrated fever and splenomegaly were present in more than 90% of the patients (fever: 70/71, 98.59%; splenomegaly: 68/71, 95.77%). Other clinical and laboratory tests included anemia (44/71, 61.97%), neutropenia (38/71, 53.52%), thrombocytopenia (33/71, 46.48%), hypofibrinogenemia (44/71, 61.97%), hypertriglyceridemia (28/71, 39.44%), hyperferritinemia (49/71, 69.01%), impaired NK-cell activity (47/71, 66.20%), and hemophagocytosis (20/24, 83.33%).
RDW, PDW, and RPR levels of the HLH patients were significantly higher than those of sepsis and normal controls. In ROC curve analysis of the RDW, PDW, and RPR for diagnosis of HLH, the area under the curve (AUC) reached to 0.78, 0.784, and 0.927, respectively. When using the criteria of RDW >13.75, PDW >13.30, and RPR >0.08, the sensitivity was 76.06%, 67.61%, and 84.51%, while the specificity was 68.57%, 85.71%, and 87.62%, respectively. After treatment of HLH patients, PDW and RPR were significantly reduced.
The authors concluded that their study indicated that cost-effective and easily calculated hematological parameters RDW, PDW, and RPR are novel indicators for differential diagnosis of HLH and sepsis. PDW and RPR could be additional biomarkers for monitoring therapeutic effects of HLH. The study was published on July 17, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Zhejiang University School of Medicine
Mindray
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data